We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Delport, Rhena![]() |
|
dc.contributor.author | Lingenhel, Arnulf W.![]() |
|
dc.contributor.author | Ubbink, Johan B.![]() |
|
dc.contributor.author | Kraft, Hans G.![]() |
|
dc.date.accessioned | 2007-10-05T12:50:47Z | |
dc.date.available | 2007-10-05T12:50:47Z | |
dc.date.issued | 2004-09 | |
dc.description.abstract | Background: Homocyst(e)ine is reported to increase the binding of lipoprotein(a) [Lp(a)] to fibrin, which may increase the thrombogenic effects of Lp(a) in vivo. The aim of this study was to investigate whether there is a relationship between homocyst(e)ine and Lp(a) levels and vascular disease risk, and if the relationship depends on the apo(a) isoforms. Methods: A case-control study was performed in 91 Caucasian male subjects with vascular disease due to athersclerosis, and in 100 healthy age- and sex-matched control subjects. Results: Both hyperhomocyst(e)inemia and elevated Lp(a) were significantly more prevalent in patients. Concordant elevated Lp(a) and hyperhomocyst(e)inemia were not associated with increased vascular disease risk (relative odds 2.96; 95% CI: 0.90-9.80), while hyperhomocyst(e)inemia in the absence of elevated Lp(a) was associated with increased vascular disease risk (relative odds 7.20; 95% CI: 2.37-21.91). Hyperhomocyst(e)inemia in individuals with high-molecular weight apo(a) isoforms [smaller apo(a) isoform > S3] was observed to be associated with increased vascular disease risk (relative odds 11.02; 95% CI: 3.54-34.30), while vascular disease risk in subjects with low-molecular weight apo(a) isoforms [smaller apo(a) isoform < S3] was not significantly increased, the relative odds being 1.92; 95% CI: 0.51-7.24. Conclusions: We conclude that hyperhomocyst(e)inemia is an important risk factor in individuals with highmolecular weight apo(a) isoforms. | en |
dc.format.extent | 373862 bytes | |
dc.format.mimetype | application/pdf | |
dc.identifier.citation | Delport, R, Lingenhel, AWM, Ubbink, JB & Kraft, HG 2004, 'Hyperhomocyst(e)inemia is an important risk factor for vascular disease in subjects with high-molecular weight apo(a) isoforms', Cardiovascular Journal of South Africa, vol. 15, no. 5, pp. 207-213. [http://www.cvjsa.co.za] | en |
dc.identifier.issn | 1680-0745 | |
dc.identifier.uri | http://hdl.handle.net/2263/3683 | |
dc.language.iso | en | en |
dc.publisher | Clinics Cardiv | en |
dc.rights | Clinics Cardiv | en |
dc.subject | Homocysteine | en |
dc.subject | Lipoprotein | en |
dc.subject | Homocystine | en |
dc.subject.lcsh | Blood-vessels--Diseases | |
dc.subject.lcsh | Homocysteine | |
dc.subject.lcsh | Lipoproteins | |
dc.title | Hyperhomocyst(e)inemia is an important risk factor for vascular disease in subjects with high-molecular weight apo(a) isoforms | en |
dc.type | Article | en |